February 20, 2026
In 2025, Colombia’s regulated export market is less about “can you ship?” and more about “can you prove every step of the shipment’s legal origin, quality controls, and custody—down to the lot and the seal number?” The compliance bar is being raised by tighter coordination between the VUCE single-window process, the multiple “visto bueno” (prior authorization) authorities, and the documentation expectations set out in Resolución Conjunta 539 de 2022 (commonly referenced in industry as “Resolution 539”), which operationalizes parts of Decreto 811 de 2021.
For exporters and foreign buyers, the practical takeaway is straightforward: customs clearance and seizure risk increasingly hinge on whether your paperwork and traceability records match across systems—VUCE filings, commercial documents, lab reports, quotas/authorizations, and transport security logs.
This article is informational only and not legal advice.
Decreto 811 de 2021 updated Colombia’s framework for regulated medical/scientific and industrial activities and opened important pathways for international trade. But the decree left a real-world gap: exporters and importers needed a detailed, inter-agency playbook for cross-border movements of seeds, plant material, derivatives, and finished products.
Resolución Conjunta 539 de 2022 filled that operational gap by:
Official references:
A common source of delays is assuming one authority’s approval is enough. Under the Resolution 539 trade scheme, the approvals are split by product category and the type of control exercised.
In 2025, exporters that perform best operationally tend to treat approvals as a single “release package,” not separate tasks. That means:
Resolution 539 formalized the trade authorization path, but most seizures and holds happen for a simpler reason: documentation mismatch. Below is a practical “documentation stack” you can build for each shipment.
Before you assemble shipment documents, confirm the legal ability to produce and export the specific material.
Include (as applicable):
Why this matters: authorities reviewing vistos buenos will often compare your request against what your license scope and controls allow.
For regulated international trade in controlled substances, the most critical document is usually the importer’s authorization.
Best practice is to obtain:
International context: the INCB describes the treaty-based requirement that exporting countries require an import authorization/certificate before issuing export authorizations. See INCB’s trade controls overview: https://i2es.incb.org/Documents/Controls%20On%20International%20Trade.pdf
One of the most common friction points in cross-border compliance is classification ambiguity—especially when the destination market distinguishes between active pharmaceutical ingredient (API), intermediate, and finished dosage form.
Build a short dossier that includes:
For shipments to the EU (or EU-aligned regimes), buyers will usually insist on:
Note: EU GMP expectations differ depending on whether the material is API (EU GMP Part II) or a finished medicinal product (EU GMP Part I), and importation into the EU triggers specific obligations for import authorization holders and QP certification. A plain-language overview is discussed here (industry compliance resource): https://www.qbdgroup.com/en/blog/importing-medicinal-products-into-eu-brief-guide-to-eu-gmp-compliance/
Colombian exporters increasingly need “export-grade” testing packages, even when not explicitly required by Colombia for every destination.
At a minimum, align COAs to:
If you use accredited labs, keep proof of accreditation scope. ONAC’s accreditation information and lab program: https://onac.org.co/servicios/laboratorios-de-ensayo/
Destination-country alignment tip:
Resolution 539’s compliance philosophy—paired with broader international controlled-trade norms—pushes exporters to maintain a defensible chain of custody.
A strong chain-of-custody pack typically includes:
Why it matters in 2025: if customs or enforcement challenges the shipment, you need to prove it is the same, unchanged lot from release to export, with controlled access throughout.
Even where the regulatory approvals are correct, commercial document mismatch is a frequent cause of holds.
Ensure consistency across:
Details that often trigger a hold:
Many exporters focus on “getting the permit,” but overlook how volume controls appear across the document stack.
Practical 2025 approach:
Colombia’s FNE publishes periodic reporting on regulated activities and includes discussion of controlled categories (example July 2025 report PDF): https://fne.minsalud.gov.co/sustancias-fiscalizadas/Informes/INFORME%20CANNABIS%20julio%202025%20publicar.pdf
Resolution 539 is not only “forms and permits”—it effectively expects exporters to operate like a controlled-pharma supply chain.
Include or implement:
Before cargo handoff, verify:
DIAN’s export basics overview is a useful refresher for exporters aligning the operational sequence: https://www.dian.gov.co/aduanas/Regimen-de-Aduanas/Documents/ABC-Aspectos-basicos-Exportacion.pdf
Foreign buyers—especially in Europe—often impose requirements beyond Colombian export authorizations.
Even when your shipment is not a finished medicinal product, EU buyers commonly want:
If you ship a finished dosage form intended for an EU market pathway, expect heavy emphasis on:
A practical overview of EU import/QP expectations: https://www.qbdgroup.com/en/blog/importing-medicinal-products-into-eu-brief-guide-to-eu-gmp-compliance/
Brazil’s Anvisa has an established process for exceptional import by individuals under RDC 660/2022. When a Colombian exporter supplies into a channel connected to individual authorizations, paperwork must match that model.
Official Anvisa service page referencing RDC 660/2022: https://www.gov.br/pt-br/servicos/solicitar-autorizacao-para-importacao-excepcional-de-produtos-a-base-de-canabidiol
Colombia’s FNE issued additional export-tramite guidance in early 2026 (relevant for 2025–2026 planning) via Circular Externa 001-2026 (PDF): https://fne.minsalud.gov.co/Style%20Library/assets/Fne_paginas/Home/Banner/22012026/CIRCULAR%20EXTERNA%20001-2026.pdf
Use the following template as a “go/no-go” internal audit before any international shipment. It is designed to reduce seizure risk and accelerate clearance.
Key systems to reference:
Even with valid authorizations, enforcement actions and delays frequently arise from:
Resolution 539’s main contribution is that it provides the inter-agency “logic” for what reviewers expect to see. In practice, your goal is to make the shipment file so coherent that an auditor can reconstruct the transaction without assumptions.
If you’re building or scaling exports, the fastest way to reduce holds is to standardize a per-shipment “export dossier” and run the pre‑export audit every time.
Use https://cannabisregulations.ai/ to track regulatory changes, build document checklists by jurisdiction, and operationalize cannabis compliance workflows for licensing, quality, and international shipment readiness.
In 2025, Colombia’s regulated export market is less about “can you ship?” and more about “can you prove every step of the shipment’s legal origin, quality controls, and custody—down to the lot and the seal number?” The compliance bar is being raised by tighter coordination between the VUCE single-window process, the multiple “visto bueno” (prior authorization) authorities, and the documentation expectations set out in Resolución Conjunta 539 de 2022 (commonly referenced in industry as “Resolution 539”), which operationalizes parts of Decreto 811 de 2021.
For exporters and foreign buyers, the practical takeaway is straightforward: customs clearance and seizure risk increasingly hinge on whether your paperwork and traceability records match across systems—VUCE filings, commercial documents, lab reports, quotas/authorizations, and transport security logs.
This article is informational only and not legal advice.
Decreto 811 de 2021 updated Colombia’s framework for regulated medical/scientific and industrial activities and opened important pathways for international trade. But the decree left a real-world gap: exporters and importers needed a detailed, inter-agency playbook for cross-border movements of seeds, plant material, derivatives, and finished products.
Resolución Conjunta 539 de 2022 filled that operational gap by:
Official references:
A common source of delays is assuming one authority’s approval is enough. Under the Resolution 539 trade scheme, the approvals are split by product category and the type of control exercised.
In 2025, exporters that perform best operationally tend to treat approvals as a single “release package,” not separate tasks. That means:
Resolution 539 formalized the trade authorization path, but most seizures and holds happen for a simpler reason: documentation mismatch. Below is a practical “documentation stack” you can build for each shipment.
Before you assemble shipment documents, confirm the legal ability to produce and export the specific material.
Include (as applicable):
Why this matters: authorities reviewing vistos buenos will often compare your request against what your license scope and controls allow.
For regulated international trade in controlled substances, the most critical document is usually the importer’s authorization.
Best practice is to obtain:
International context: the INCB describes the treaty-based requirement that exporting countries require an import authorization/certificate before issuing export authorizations. See INCB’s trade controls overview: https://i2es.incb.org/Documents/Controls%20On%20International%20Trade.pdf
One of the most common friction points in cross-border compliance is classification ambiguity—especially when the destination market distinguishes between active pharmaceutical ingredient (API), intermediate, and finished dosage form.
Build a short dossier that includes:
For shipments to the EU (or EU-aligned regimes), buyers will usually insist on:
Note: EU GMP expectations differ depending on whether the material is API (EU GMP Part II) or a finished medicinal product (EU GMP Part I), and importation into the EU triggers specific obligations for import authorization holders and QP certification. A plain-language overview is discussed here (industry compliance resource): https://www.qbdgroup.com/en/blog/importing-medicinal-products-into-eu-brief-guide-to-eu-gmp-compliance/
Colombian exporters increasingly need “export-grade” testing packages, even when not explicitly required by Colombia for every destination.
At a minimum, align COAs to:
If you use accredited labs, keep proof of accreditation scope. ONAC’s accreditation information and lab program: https://onac.org.co/servicios/laboratorios-de-ensayo/
Destination-country alignment tip:
Resolution 539’s compliance philosophy—paired with broader international controlled-trade norms—pushes exporters to maintain a defensible chain of custody.
A strong chain-of-custody pack typically includes:
Why it matters in 2025: if customs or enforcement challenges the shipment, you need to prove it is the same, unchanged lot from release to export, with controlled access throughout.
Even where the regulatory approvals are correct, commercial document mismatch is a frequent cause of holds.
Ensure consistency across:
Details that often trigger a hold:
Many exporters focus on “getting the permit,” but overlook how volume controls appear across the document stack.
Practical 2025 approach:
Colombia’s FNE publishes periodic reporting on regulated activities and includes discussion of controlled categories (example July 2025 report PDF): https://fne.minsalud.gov.co/sustancias-fiscalizadas/Informes/INFORME%20CANNABIS%20julio%202025%20publicar.pdf
Resolution 539 is not only “forms and permits”—it effectively expects exporters to operate like a controlled-pharma supply chain.
Include or implement:
Before cargo handoff, verify:
DIAN’s export basics overview is a useful refresher for exporters aligning the operational sequence: https://www.dian.gov.co/aduanas/Regimen-de-Aduanas/Documents/ABC-Aspectos-basicos-Exportacion.pdf
Foreign buyers—especially in Europe—often impose requirements beyond Colombian export authorizations.
Even when your shipment is not a finished medicinal product, EU buyers commonly want:
If you ship a finished dosage form intended for an EU market pathway, expect heavy emphasis on:
A practical overview of EU import/QP expectations: https://www.qbdgroup.com/en/blog/importing-medicinal-products-into-eu-brief-guide-to-eu-gmp-compliance/
Brazil’s Anvisa has an established process for exceptional import by individuals under RDC 660/2022. When a Colombian exporter supplies into a channel connected to individual authorizations, paperwork must match that model.
Official Anvisa service page referencing RDC 660/2022: https://www.gov.br/pt-br/servicos/solicitar-autorizacao-para-importacao-excepcional-de-produtos-a-base-de-canabidiol
Colombia’s FNE issued additional export-tramite guidance in early 2026 (relevant for 2025–2026 planning) via Circular Externa 001-2026 (PDF): https://fne.minsalud.gov.co/Style%20Library/assets/Fne_paginas/Home/Banner/22012026/CIRCULAR%20EXTERNA%20001-2026.pdf
Use the following template as a “go/no-go” internal audit before any international shipment. It is designed to reduce seizure risk and accelerate clearance.
Key systems to reference:
Even with valid authorizations, enforcement actions and delays frequently arise from:
Resolution 539’s main contribution is that it provides the inter-agency “logic” for what reviewers expect to see. In practice, your goal is to make the shipment file so coherent that an auditor can reconstruct the transaction without assumptions.
If you’re building or scaling exports, the fastest way to reduce holds is to standardize a per-shipment “export dossier” and run the pre‑export audit every time.
Use https://cannabisregulations.ai/ to track regulatory changes, build document checklists by jurisdiction, and operationalize cannabis compliance workflows for licensing, quality, and international shipment readiness.
